Medical Pharmacology: Chapter 37 — Antifungal Agents -- Module 1 — Polyene Antifungals: Amphotericin B Formulations and Nystatin

Chapter 37 — Antifungal Agents — Module 1 — Polyene Antifungals: Amphotericin B Formulations and Nystatin

1. A 61-year-old man with acute myeloid leukemia is on day 19 of induction chemotherapy. His absolute neutrophil count is 60 cells/mm³. Blood cultures drawn for fever grow Candida tropicalis. Susceptibility testing confirms fluconazole susceptibility. The hematology team asks whether fluconazole or amphotericin B deoxycholate is preferred for treatment. Which of the following best justifies the choice of amphotericin B in this clinical context?

A) Amphotericin B is preferred because Candida tropicalis is uniformly resistant to fluconazole in patients who have received prior azole prophylaxis, and empirical azole therapy would fail due to pre-existing resistance regardless of in vitro susceptibility results
B) Amphotericin B is preferred because it achieves urine concentrations 50-fold higher than fluconazole, providing superior coverage for the renal parenchymal seeding that invariably accompanies Candida tropicalis fungemia and is the primary source of mortality in this setting
C) Amphotericin B is preferred because it is fungicidal — it directly kills Candida tropicalis through transmembrane pore formation and irreversible membrane depolarization — whereas fluconazole is fungistatic, leaving residual viable organisms whose elimination depends on neutrophil-mediated phagocytosis; with an absolute neutrophil count of 60 cells/mm³, phagocytic clearance is absent and fungistatic therapy alone is insufficient
D) Amphotericin B is preferred because it has a broader spectrum than fluconazole and covers the Candida krusei and Candida glabrata species that commonly co-infect with Candida tropicalis in neutropenic hosts, providing dual-species empirical coverage that fluconazole cannot
E) Amphotericin B is preferred because fluconazole requires intact hepatic CYP2C9 metabolism for activation to its antifungal form, and chemotherapy-induced hepatotoxicity in this patient impairs fluconazole bioactivation and renders it ineffective at standard doses

ANSWER: C

Rationale:

The pharmacodynamic distinction between fungicidal and fungistatic activity is clinically decisive in this case. Fluconazole inhibits lanosterol 14-alpha-demethylase, blocking ergosterol synthesis and arresting fungal growth — but it does not directly kill Candida organisms. Residual viable cells persist under fluconazole therapy and require host phagocytic clearance, primarily neutrophil-mediated, to achieve cure. In a patient whose absolute neutrophil count is 60 cells/mm³, this clearance mechanism is effectively absent. Amphotericin B, by contrast, is fungicidal: it binds ergosterol in the fungal cell membrane and self-assembles into transmembrane pores that cause irreversible potassium efflux, membrane depolarization, and direct cell death — independently of host immune function. This fungicidal killing mechanism is the pharmacodynamic rationale for preferring AmB in severely neutropenic hosts with candidemia, even when fluconazole susceptibility is confirmed in vitro.

Option A: Option A is incorrect; Candida tropicalis is not uniformly resistant to fluconazole in azole-prophylaxed patients — while acquired resistance is a concern with prolonged prophylaxis, the stem confirms in vitro susceptibility, and intrinsic fluconazole resistance is not a characteristic of C. tropicalis.
Option B: Option B is incorrect; the superior killing rationale for AmB is its fungicidal mechanism, not urine concentration advantages — and the claim of 50-fold higher urine concentrations compared to fluconazole is not accurate pharmacology.
Option D: Option D is incorrect; Candida krusei and Candida glabrata do not routinely co-infect with C. tropicalis, and the clinical decision is based on the confirmed C. tropicalis infection, not empirical multi-species coverage.
Option E: Option E is incorrect; fluconazole is not a prodrug requiring CYP2C9 bioactivation — it is the active form as administered and is not rendered ineffective by hepatotoxicity in the manner described.

2. A 44-year-old woman with HIV and a CD4 count of 28 cells/mm³ is being treated for Cryptococcus neoformans meningitis with amphotericin B deoxycholate 1.0 mg/kg/day plus flucytosine. Sodium loading with 500 mL normal saline has been given before each infusion. Her baseline creatinine was 0.8 mg/dL. On day 8, her creatinine is 1.7 mg/dL. Which of the following is the most appropriate next step in antifungal management?

A) Continue amphotericin B deoxycholate at the current dose and increase sodium loading to 1000 mL of normal saline before each infusion, because doubling the pre-hydration volume is the recommended intervention when creatinine rises during sodium-loaded AmBd therapy before formulation switch is considered
B) Discontinue all amphotericin B and transition to high-dose fluconazole 800 mg daily, because any creatinine rise above 1.5 mg/dL is an absolute contraindication to all amphotericin B formulations including liposomal preparations
C) Reduce the amphotericin B deoxycholate dose to 0.5 mg/kg/day and reassess creatinine in 72 hours, because dose reduction is the first-line intervention for nephrotoxicity in patients requiring ongoing therapy for life-threatening CNS infection
D) Continue amphotericin B deoxycholate unchanged and attribute the creatinine rise to flucytosine-induced nephrotoxicity rather than AmBd, discontinuing flucytosine while continuing the polyene component at full dose
E) Switch from amphotericin B deoxycholate to liposomal amphotericin B because creatinine has doubled from baseline — from 0.8 to 1.7 mg/dL — meeting the standard threshold for formulation change; continuing AmBd risks further cumulative tubular damage that may be only partially reversible, while L-AmB provides equivalent antifungal efficacy with substantially reduced nephrotoxicity

ANSWER: E

Rationale:

A doubling of serum creatinine from baseline is the established clinical threshold triggering formulation switch from amphotericin B deoxycholate to a lipid formulation. In this patient, creatinine has risen from 0.8 to 1.7 mg/dL — more than doubling — despite sodium loading. The rationale for switching rather than dose-reducing or volume-escalating is that AmBd nephrotoxicity is cumulative and dose-dependent, and at higher cumulative exposures, tubular damage can produce persistent renal impairment that does not fully resolve after drug discontinuation. Sodium loading reduces but does not eliminate nephrotoxicity risk, and its nephroprotective effect is diminished once active tubular injury is under way. Liposomal amphotericin B at 3 to 5 mg/kg/day delivers equivalent antifungal efficacy with substantially reduced nephrotoxicity by shielding AmB from renal tubular cholesterol within the liposomal carrier. Maintaining antifungal therapy throughout is essential given active cryptococcal meningitis.

Option A: Option A is incorrect; doubling the sodium loading volume is not the recommended intervention once the creatinine-doubling threshold has been crossed — sodium loading is a preventive measure, not a treatment for established tubular injury, and 1000 mL may precipitate volume overload.
Option B: Option B is incorrect; a creatinine above 1.5 mg/dL is not an absolute contraindication to all AmB formulations — lipid formulations are specifically designed for patients who cannot tolerate AmBd nephrotoxicity, and fluconazole monotherapy is inferior to AmB-based induction for cryptococcal meningitis.
Option C: Option C is incorrect; dose reduction of AmBd is not the standard evidence-based response to creatinine doubling — formulation switch to a lipid preparation is the established approach.
Option D: Option D is incorrect; flucytosine does not cause the pattern of nephrotoxicity seen here — tubular potassium and magnesium wasting with creatinine rise is the signature of AmBd toxicity, not 5-FC toxicity, and discontinuing flucytosine while continuing AmBd removes a synergistic component without addressing the nephrotoxic agent.

3. A 52-year-old liver transplant recipient maintained on tacrolimus develops invasive candidiasis confirmed by blood culture. He is concurrently receiving tobramycin for a Pseudomonas aeruginosa bacteremia that cannot be discontinued. His baseline creatinine is 1.4 mg/dL and anticipated antifungal treatment duration is at least three weeks. The team is choosing between amphotericin B deoxycholate with sodium loading and liposomal amphotericin B. Which of the following correctly identifies the independent risk factors that mandate upfront lipid formulation use in this patient?

A) This patient has three independent indications for upfront liposomal amphotericin B: solid organ transplant recipient status with concurrent calcineurin inhibitor use producing additive pharmacodynamic nephrotoxicity; concurrent aminoglycoside use that cannot be discontinued; and anticipated treatment duration exceeding two weeks — each factor alone warrants lipid formulation initiation, and their combination makes AmBd initiation clearly inappropriate
B) This patient has one indication for lipid formulation use — concurrent tobramycin — but the transplant status and tacrolimus use do not independently warrant lipid formulation because calcineurin inhibitor nephrotoxicity is managed by tacrolimus dose reduction rather than antifungal formulation change
C) The only mandatory indication for lipid formulation use in this patient is his baseline creatinine of 1.4 mg/dL, which exceeds the 1.0 mg/dL threshold for lipid formulation initiation; transplant status and concurrent nephrotoxin use are relative rather than absolute indications that do not independently mandate lipid formulation
D) Liposomal amphotericin B is not indicated in this patient because his creatinine of 1.4 mg/dL is below the 2.5 mg/dL absolute threshold, and reactive switching after creatinine doubles during AmBd therapy is the guideline-recommended approach that avoids the unnecessary cost of upfront lipid formulation use
E) This patient requires amphotericin B deoxycholate with aggressive sodium loading at 1000 mL before each infusion rather than a lipid formulation, because the superior antifungal efficacy of AmBd over L-AmB in organ transplant recipients with invasive candidiasis justifies accepting a higher nephrotoxicity risk when treating this infection category

ANSWER: A

Rationale:

This patient carries three independent indications for initiating liposomal amphotericin B from the outset rather than starting with AmBd. First, solid organ transplant recipient status with concurrent tacrolimus use: tacrolimus causes afferent arteriolar vasoconstriction through calcineurin inhibition-mediated reduction in vasodilatory prostaglandins, compounding AmBd's own vasoconstrictor mechanism and producing additive nephrotoxicity through independent pharmacodynamic pathways. Second, concurrent aminoglycoside use (tobramycin) that cannot be discontinued given active Pseudomonas bacteremia: aminoglycosides are directly nephrotoxic through proximal tubular accumulation and cannot be safely combined with AmBd in most clinical settings without substantial renal injury risk. Third, anticipated treatment duration exceeding two weeks: prolonged AmBd exposure is associated with cumulative and potentially irreversible tubular damage. The prescribing principle is clear: lipid formulation use should be decided proactively before initiating therapy, not reactively after nephrotoxicity develops.

Option B: Option B is incorrect; transplant status with concurrent calcineurin inhibitor use is an independent indication for lipid formulation use — the pharmacodynamic interaction between tacrolimus and AmBd cannot be managed by tacrolimus dose reduction alone, as the additive tubular and vascular toxicities are mechanistically independent of tacrolimus trough levels.
Option C: Option C is incorrect; there is no established 1.0 mg/dL creatinine threshold as a mandatory trigger — the relevant threshold is 2.5 mg/dL or CrCl below 25 mL/min, and transplant status, concurrent nephrotoxins, and treatment duration are independent indications regardless of baseline creatinine.
Option D: Option D is incorrect; reactive switching after creatinine doubling is explicitly the strategy the prescribing framework advises against in high-risk patients — proactive lipid formulation initiation is indicated when multiple risk factors are present before therapy begins.
Option E: Option E is incorrect; AmBd does not have demonstrated superior antifungal efficacy over L-AmB in transplant recipients with invasive candidiasis — the lipid formulations are non-inferior in efficacy with superior tolerability, and there is no efficacy rationale for accepting higher nephrotoxicity risk in this setting.

4. A 39-year-old man with invasive aspergillosis is receiving his fourth amphotericin B deoxycholate infusion. He received acetaminophen 650 mg and diphenhydramine 50 mg 45 minutes before the infusion. Thirty minutes into the infusion he develops violent shaking chills with a temperature of 39.6°C and heart rate of 124 beats per minute. The nurse asks what agent should be given immediately to break the rigors and whether this reaction means the drug must be permanently discontinued. Which of the following is correct?

A) Lorazepam 2 mg IV should be administered because benzodiazepine-mediated muscle relaxation directly terminates shivering by blocking gamma-aminobutyric acid receptors in the spinal cord interneurons responsible for coordinating the shivering motor pattern; this reaction does not preclude continued use
B) Naloxone 0.4 mg IV should be administered because amphotericin B-induced rigors are mediated through endogenous kappa-opioid receptor activation in the hypothalamus; naloxone displaces the endogenous opioid and resets the thermostat; the reaction does not represent drug allergy
C) The infusion should be stopped permanently and the patient transitioned to voriconazole because this reaction on the fourth infusion, despite premedication, represents progressive IgE-mediated sensitization that will culminate in anaphylaxis on subsequent exposures if amphotericin B is continued
D) Meperidine 25 to 50 mg IV should be administered; it terminates rigors by acting on mu-opioid receptors in the hypothalamus to reset the thermoregulatory set point; this reaction is not IgE-mediated, does not represent drug allergy, does not predict anaphylaxis, and does not contraindicate continued amphotericin B therapy — reactions typically diminish in severity with subsequent infusions as tolerance develops
E) Indomethacin 50 mg IV should be administered because amphotericin B rigors are driven exclusively by cyclooxygenase-2-mediated prostaglandin E2 production in the hypothalamus; cyclooxygenase inhibition is the most targeted intervention and is preferred over opioid-based agents because it avoids respiratory depression in a patient with pulmonary aspergillosis

ANSWER: D

Rationale:

Amphotericin B deoxycholate infusion reactions are mediated through toll-like receptor 2 and toll-like receptor 4 signaling in monocytes and macrophages, stimulating release of prostaglandins, interleukin-1, and tumor necrosis factor-alpha, along with complement activation via the alternative pathway. This mechanism is not IgE-mediated, does not represent true drug allergy, does not predict anaphylaxis, and does not contraindicate continued AmBd use. For established rigors that have broken through acetaminophen and diphenhydramine premedication, meperidine 25 to 50 mg IV is the specific rescue agent. Meperidine acts on mu-opioid receptors in the hypothalamus to reset the thermoregulatory set point, directly interrupting the shivering response driven by the cytokine-mediated pyrogenic cascade. Reactions characteristically diminish in severity with repeated infusions as tolerance develops.

Option A: Option A is incorrect; lorazepam is not used for AmBd-associated rigors — benzodiazepines provide muscle relaxation through GABA-A receptors but do not address the hypothalamic thermostat drive sustaining the rigors, and GABA-A-mediated spinal cord interneuron blockade is not the established mechanism of rigor termination in this setting.
Option B: Option B is incorrect; naloxone is an opioid antagonist and would block the very receptor pathway used therapeutically by meperidine — its administration would be counterproductive, and the proposed mechanism of endogenous kappa-opioid-mediated rigors displaced by naloxone is not established pharmacology for AmBd reactions.
Option C: Option C is incorrect; this reaction is not IgE-mediated and does not represent progressive sensitization toward anaphylaxis — interpreting cytokine-driven infusion reactions as allergic and discontinuing an effective antifungal for invasive aspergillosis would be a serious management error.
Option E: Option E is incorrect; while prostaglandins do contribute to the febrile component of AmBd reactions, indomethacin IV is not the established agent for terminating rigors, and cyclooxygenase inhibition alone does not reliably break established shivering — meperidine's direct hypothalamic effect is the mechanism of choice for this specific clinical problem.

5. A 74-year-old man with ischemic cardiomyopathy (ejection fraction 15%) and bilateral pulmonary edema on chest X-ray is admitted with invasive pulmonary histoplasmosis. The infectious disease team plans amphotericin B deoxycholate therapy. A trainee suggests using standard sodium loading — 500 mL of normal saline before each infusion — to reduce nephrotoxicity risk. Which of the following best describes the correct approach to nephroprotection in this patient?

A) Sodium loading should proceed as planned because the nephroprotective benefit of pre-hydration outweighs the volume risk in compensated heart failure; the loop diuretic dose should be empirically doubled on infusion days to offset the 500 mL volume load
B) Sodium loading is contraindicated in this patient because the 500 mL isotonic saline volume load is intolerable in a patient with an ejection fraction of 15% and active pulmonary edema; liposomal amphotericin B should be used from the outset, providing nephroprotection through the liposomal delivery mechanism without requiring volume preloading
C) Sodium loading should be replaced with 250 mL of 0.45% half-normal saline, providing sufficient sodium delivery to reduce tubuloglomerular feedback-mediated vasoconstriction at half the volume burden; this modification makes sodium loading safe in decompensated heart failure
D) Sodium loading is unnecessary for this patient because amphotericin B deoxycholate nephrotoxicity is driven entirely by direct tubular pore formation rather than afferent arteriolar vasoconstriction, and sodium delivery to the distal tubule does not reduce the tubular component of nephrotoxicity
E) Sodium loading should be deferred for the first five infusions while the heart failure is actively managed; once the patient is euvolemic, sodium loading can be safely introduced and AmBd continued at full dose with standard pre-hydration

ANSWER: B

Rationale:

Sodium loading with 500 mL of 0.9% normal saline before each AmBd infusion is the evidence-based strategy for nephroprotection, operating through volume expansion that reduces tubuloglomerular feedback-mediated afferent arteriolar vasoconstriction, increased distal tubular sodium delivery competing with potassium wasting, and dilution of free plasma drug concentration. However, this strategy is explicitly contraindicated in patients with severe heart failure, pulmonary edema, or anasarca — conditions in which the added intravascular volume cannot be tolerated without precipitating decompensation. In a patient with an ejection fraction of 15% and active bilateral pulmonary edema, adding 500 mL of isotonic saline before every infusion carries a high risk of acute cardiorespiratory decompensation. The correct approach is to use a lipid amphotericin B formulation from the outset. L-AmB provides nephroprotection through the liposomal shielding mechanism — the liposomal carrier intercepts drug before it reaches renal tubular cholesterol — without requiring volume preloading.

Option A: Option A is incorrect; doubling the loop diuretic dose on infusion days is not a validated or reliable substitute for avoiding the volume load, and managing aggressive diuresis around each AmBd infusion adds complexity and risk without addressing the fundamental problem.
Option C: Option C is incorrect; half-normal saline provides weaker osmotic volume expansion and less sodium delivery — it is not a validated replacement for isotonic saline in this indication, and the fluid restriction problem in decompensated heart failure persists regardless of the sodium concentration selected.
Option D: Option D is incorrect; AmBd nephrotoxicity involves both afferent arteriolar vasoconstriction and distal tubular damage — dismissing the vasoconstrictive component and the sodium delivery mechanism as irrelevant is pharmacologically inaccurate.
Option E: Option E is incorrect; deferring sodium loading while continuing AmBd during active management of heart failure does not constitute a sound strategy — AmBd nephrotoxicity can develop acutely and the lipid formulation should replace AmBd entirely in this patient, not be deferred.

6. A 55-year-old woman on day 10 of amphotericin B deoxycholate for invasive aspergillosis has a serum potassium of 2.5 mEq/L despite receiving 180 mEq of intravenous potassium chloride over the preceding 24 hours. Her serum magnesium is 0.9 mg/dL. Her creatinine has risen from a baseline of 0.9 to 1.6 mg/dL. The team asks how to address the refractory hypokalemia. Which of the following is the correct next step?

A) Increase the intravenous potassium chloride replacement to 300 mEq over the next 24 hours because refractory hypokalemia in the setting of amphotericin B therapy requires higher replacement doses than are used in other clinical contexts and standard doses are insufficient to overcome the continuous renal wasting
B) Add spironolactone 50 mg twice daily to block mineralocorticoid receptor-mediated potassium wasting in the collecting duct because secondary hyperaldosteronism is the primary mechanism of refractory hypokalemia in patients receiving amphotericin B for more than one week
C) Administer magnesium supplementation — intravenous magnesium sulfate or oral magnesium oxide — before escalating potassium replacement further; hypomagnesemia at this level impairs the renal outer medullary potassium channel responsible for distal tubular potassium reabsorption, and potassium deficits cannot be corrected until magnesium is repleted; simultaneously, the creatinine doubling from baseline warrants switching from AmBd to liposomal amphotericin B
D) Switch from intravenous potassium chloride to oral potassium gluconate because the chloride salt paradoxically worsens renal tubular dysfunction in amphotericin B-treated patients through chloride-mediated inhibition of the distal tubular sodium-potassium-ATPase, whereas the gluconate formulation bypasses this inhibitory interaction
E) Discontinue amphotericin B immediately and allow spontaneous potassium recovery over 72 hours without further supplementation because the tubular dysfunction causing potassium wasting is rapidly reversible upon drug discontinuation and aggressive replacement risks rebound hyperkalemia

ANSWER: C

Rationale:

This case illustrates two concurrent management imperatives that must both be addressed. First, the refractory hypokalemia despite massive potassium replacement is explained by the concurrent severe hypomagnesemia. Magnesium is required for normal function of the renal outer medullary potassium (ROMK) channel in the distal nephron; when serum magnesium falls to 0.9 mg/dL, ROMK channel function is impaired and urinary potassium wasting continues regardless of the amount of potassium administered. Potassium deficits cannot be corrected until magnesium is repleted — intravenous magnesium sulfate or oral magnesium oxide must be provided concurrently with continued potassium replacement. Second, the creatinine has risen from 0.9 to 1.6 mg/dL — nearly doubling from baseline — meeting the standard threshold for switching from AmBd to a lipid amphotericin B formulation to prevent further cumulative tubular damage. Both actions should occur simultaneously.

Option A: Option A is incorrect; simply escalating the potassium dose will not overcome refractory hypokalemia caused by ROMK channel impairment from hypomagnesemia — the root cause must be addressed before replacement can be effective.
Option B: Option B is incorrect; secondary hyperaldosteronism is not the primary mechanism of AmBd-associated hypokalemia — the mechanism is direct distal tubular pore-mediated potassium wasting, not aldosterone excess, and spironolactone is not the standard intervention.
Option D: Option D is incorrect; the switch from IV potassium chloride to oral potassium gluconate does not address the ROMK channel impairment caused by hypomagnesemia, and the proposed mechanism of chloride-mediated Na-K-ATPase inhibition is pharmacologically fabricated.
Option E: Option E is incorrect; serum potassium of 2.5 mEq/L carries risk of cardiac arrhythmias and cannot safely be left to spontaneous recovery over 72 hours — active replacement with concurrent magnesium repletion is required, and formulation switch rather than drug discontinuation is the appropriate response to the creatinine doubling.

7. A 67-year-old man with chronic lymphocytic leukemia undergoing chemotherapy develops persistent candidemia despite five days of empirical liposomal amphotericin B. Repeat blood cultures remain positive. The organism is initially reported as Candida parapsilosis complex by automated identification; MALDI-TOF mass spectrometry reclassification identifies it as Candida lusitaniae. Which of the following best explains the treatment failure and the appropriate change in management?

A) The treatment failure reflects inadequate liposomal amphotericin B dosing for Candida lusitaniae, which requires dose escalation to 10 mg/kg/day to overcome the higher minimum inhibitory concentrations characteristic of this species; the formulation should be maintained but the dose escalated
B) The treatment failure reflects biofilm formation by Candida lusitaniae on the central venous catheter that is impenetrable to all amphotericin B formulations; catheter removal alone without antifungal change will resolve the candidemia once the biofilm source is eliminated
C) The treatment failure reflects Candida lusitaniae development of acquired resistance during the five-day treatment course through upregulation of CDR1 efflux pumps; switching to an echinocandin is appropriate because echinocandins are not substrates for CDR1-mediated efflux
D) The treatment failure is unrelated to antifungal coverage — Candida lusitaniae and Candida parapsilosis have identical susceptibility profiles to all antifungal classes including amphotericin B, and the persistent candidemia reflects host immune failure rather than inadequate drug activity
E) Candida lusitaniae has intrinsic amphotericin B resistance through constitutive ERG3 gene mutations that reduce membrane ergosterol content, eliminating the drug's pharmacological target; dose escalation of any amphotericin B formulation cannot overcome this intrinsic resistance, and therapy must be changed to an agent with demonstrated activity — typically an echinocandin or azole guided by susceptibility testing

ANSWER: E

Rationale:

Candida lusitaniae is one of the most clinically significant spectrum gaps for the polyene antifungal class. Its intrinsic resistance to all amphotericin B formulations arises from constitutive ERG3 gene mutations encoding C-5 sterol desaturase. These mutations alter the ergosterol biosynthesis pathway such that the fungal cell membrane has reduced ergosterol content, directly eliminating the pharmacological target for AmB. Because the resistance is constitutive — present in all isolates of the species as an inherent genetic characteristic, not acquired during therapy — no dose escalation or formulation change within the polyene class can reliably overcome it. The persistent candidemia despite five days of liposomal AmB is the expected consequence of treating a constitutively resistant organism with a drug that has no functional target in that organism's membrane. This case also illustrates the critical importance of species-level identification: the automated system misidentified C. lusitaniae as C. parapsilosis complex, which would be susceptible to AmB, delaying recognition of the coverage gap. Management requires transition to an antifungal class with demonstrated activity — typically an echinocandin (preferred for Candida candidemia) or azole, guided by susceptibility testing.

Option A: Option A is incorrect; dose escalation to 10 mg/kg/day does not overcome intrinsic ergosterol-target-based resistance — the target is absent or insufficient regardless of drug concentration, and the AmBiLoad trial established that 10 mg/kg/day provides no efficacy benefit over standard dosing even in susceptible organisms.
Option B: Option B is incorrect; while catheter removal is an important adjunct in candidemia management, the primary cause of treatment failure here is the intrinsic AmB resistance of C. lusitaniae, not catheter biofilm — catheter removal alone without antifungal change would not achieve cure.
Option C: Option C is incorrect; C. lusitaniae resistance to AmB is constitutive and mechanism-based (reduced ergosterol), not acquired through CDR1 efflux pump upregulation — CDR1 efflux is a mechanism of azole resistance, not polyene resistance.
Option D: Option D is incorrect; Candida lusitaniae and Candida parapsilosis do not have identical susceptibility profiles — the intrinsic AmB resistance of C. lusitaniae is a defining pharmacological characteristic that directly explains the treatment failure.

8. A 58-year-old woman with poorly controlled type 2 diabetes presents with three days of worsening left orbital swelling, black nasal eschar, and diplopia. MRI shows invasion of the left orbit and cavernous sinus. Biopsy of the nasal mucosa shows broad, ribbon-like hyphae with rare septations. Empirical liposomal amphotericin B at 5 mg/kg/day is started immediately. Surgical debridement is performed. On day four, the mold isolate from the biopsy is identified as Scedosporium apiospermum. Which of the following best describes the implication of this identification for ongoing antifungal management?

A) Scedosporium apiospermum is intrinsically resistant to all formulations of amphotericin B and the current liposomal amphotericin B regimen is ineffective; antifungal therapy must be changed to voriconazole, which is the agent of choice for Scedosporium infections
B) Scedosporium apiospermum is susceptible to liposomal amphotericin B but resistant to conventional amphotericin B deoxycholate; since the patient is receiving the liposomal formulation, the current regimen remains appropriate and no change is needed
C) The identification of Scedosporium apiospermum should be treated as a laboratory contaminant because its histological appearance — broad aseptate hyphae — is pathognomonic for Mucorales and cannot represent Scedosporium, which produces septate narrow hyphae distinct from those observed in this biopsy
D) Scedosporium apiospermum is susceptible to amphotericin B only at doses exceeding 7 mg/kg/day; the current dose of 5 mg/kg/day should be escalated to 10 mg/kg/day to achieve minimum inhibitory concentrations against this organism while maintaining the liposomal formulation
E) Scedosporium apiospermum susceptibility to amphotericin B varies by geographic region, with North American isolates uniformly susceptible and Asian isolates resistant; susceptibility testing is required to determine whether the current regimen is appropriate before any therapy change is made

ANSWER: A

Rationale:

Scedosporium apiospermum is intrinsically resistant to all formulations of amphotericin B — conventional and lipid-based alike. This is a clinically critical spectrum gap because rhinoorbital-cerebral invasive mold infections present similarly regardless of whether the causative organism is Mucorales (for which AmB is active) or Scedosporium (for which it is not). The histological appearance of broad, relatively pauciseptate hyphae, while more characteristic of Mucorales, does not reliably exclude Scedosporium, which can appear less distinctly septate on some preparations. Culture or molecular identification is therefore essential. The identification of S. apiospermum means the patient has been receiving ineffective antifungal therapy for four days and the regimen must be changed immediately. Voriconazole is the agent of choice for Scedosporium infections, with demonstrated activity against S. apiospermum in clinical and in vitro data.

Option B: Option B is incorrect; intrinsic resistance to amphotericin B in Scedosporium is a class effect — it applies to all AmB formulations including L-AmB, not only to conventional AmBd. The liposomal vehicle reduces toxicity but does not alter the drug's antifungal spectrum against intrinsically resistant organisms.
Option C: Option C is incorrect; while the histological picture of broad pauciseptate hyphae is more characteristic of Mucorales, Scedosporium can produce a similar appearance and cannot be excluded on histology alone — this is precisely why culture results are definitive and should not be dismissed as contaminants when they identify clinically relevant species.
Option D: Option D is incorrect; dose escalation of L-AmB does not overcome intrinsic resistance — the resistance mechanism (reduced ergosterol target or alternative membrane sterol composition) is not concentration-dependent and cannot be overcome by higher dosing of an inactive drug class.
Option E: Option E is incorrect; Scedosporium apiospermum resistance to amphotericin B is not geographic — it is a constitutive characteristic of the species, and susceptibility testing would not identify susceptible isolates because the intrinsic resistance is consistent across clinical isolates.

9. A 33-year-old man with HIV and a CD4 count of 19 cells/mm³ is diagnosed with Cryptococcus neoformans meningitis. He is started on amphotericin B deoxycholate plus flucytosine induction therapy. He asks his physician why he needs two antifungal drugs when one should be enough. Which of the following most accurately explains the pharmacodynamic rationale for the combination in terms the patient's team could use to justify the regimen?

A) The two drugs are used together because flucytosine prevents amphotericin B from causing nephrotoxicity by chelating free AmBd in the bloodstream before it reaches the renal vasculature, allowing a higher and more effective amphotericin B dose to be used safely with lower kidney risk than monotherapy
B) The two drugs are used together because Cryptococcus neoformans has intrinsic resistance to amphotericin B in the central nervous system compartment where CSF concentrations of AmBd are less than 4% of plasma levels; flucytosine is added specifically to compensate for the inadequate AmBd CSF penetration by providing direct CSF antifungal activity
C) The two drugs are used together because flucytosine and amphotericin B both inhibit ergosterol biosynthesis at different steps in the same pathway, producing additive depletion of the membrane ergosterol that both drugs require as a structural target for their respective mechanisms
D) Amphotericin B forms pores in the Cryptococcus membrane that increase its permeability, allowing more flucytosine to enter the fungal cell than would be possible otherwise; once inside, flucytosine is converted to metabolites that disrupt fungal RNA and block DNA synthesis — the combination kills the organism at drug concentrations below what either drug alone requires, producing faster clearance of Cryptococcus from the CSF than monotherapy
E) The two drugs are used together because amphotericin B is active only against the yeast form of Cryptococcus neoformans while flucytosine is active only against the hyphal form; Cryptococcus can switch between forms in the CSF under drug pressure, and monotherapy with either agent selects for the resistant form while combination therapy covers both morphological states

ANSWER: D

Rationale:

The pharmacodynamic synergy between amphotericin B and flucytosine (5-FC) against Cryptococcus neoformans is mechanistically sequential and clinically well validated. Amphotericin B forms transmembrane pores in the fungal cell membrane through ergosterol binding and oligomeric pore assembly, increasing membrane permeability for small molecules. This enhanced permeability enables more flucytosine to enter the fungal cell than passive diffusion alone would allow. Inside the cell, fungal cytosine deaminase converts 5-FC to 5-fluorouracil (5-FU), which is metabolized to metabolites that disrupt fungal RNA integrity (inhibiting protein synthesis) and inhibit thymidylate synthase (blocking DNA synthesis). The result is fungicidal activity against Cryptococcus at drug concentrations below the minimum inhibitory concentration of either agent alone, and clinical trial data demonstrate superior CSF sterilization rates compared to AmB monotherapy. Faster CSF sterilization translates to reduced mortality in cryptococcal meningitis.

Option A: Option A is incorrect; flucytosine does not chelate amphotericin B or reduce its nephrotoxicity — this mechanism is entirely fabricated and has no pharmacological basis.
Option B: Option B is incorrect; Cryptococcus neoformans does not have intrinsic resistance to AmB in the CNS — AmBd is effective for cryptococcal meningitis despite low CSF penetration because therapeutic concentrations accumulate in the meninges and choroid plexus; and the rationale for adding 5-FC is synergistic killing, not compensation for AmBd CSF penetration failure.
Option C: Option C is incorrect; neither amphotericin B nor flucytosine inhibits ergosterol biosynthesis — AmB binds pre-formed ergosterol in the assembled membrane, and 5-FC targets nucleic acid synthesis, not the ergosterol pathway.
Option E: Option E is incorrect; Cryptococcus neoformans does not switch between morphological forms under antifungal drug pressure in the way described, and neither drug has activity restricted to a single morphological state of this pathogen.

10. A 26-year-old woman at 10 weeks gestation develops oropharyngeal candidiasis while on inhaled corticosteroids for asthma. She asks her obstetrician whether antifungal treatment is safe during pregnancy. Which of the following best describes the appropriate antifungal selection and the pharmacological basis for its safety in this patient?

A) Systemic fluconazole 150 mg orally as a single dose is the preferred treatment because its safety in the first trimester is well established from multiple large prospective cohort studies, and oral fluconazole achieves mucosal drug concentrations far superior to nystatin swish-and-swallow, making it the more effective choice for oropharyngeal candidiasis in pregnancy
B) Nystatin oral suspension swished around the mouth and swallowed is appropriate for oropharyngeal candidiasis in this patient; because nystatin is not absorbed from the gastrointestinal tract, systemic drug exposure to the fetus does not occur, making it the safe first-line option for mucosal candidiasis during pregnancy where systemic azoles are generally avoided
C) No antifungal treatment is needed because oropharyngeal candidiasis is self-limiting in immunocompetent pregnant patients and always resolves spontaneously within two weeks; antifungal treatment during the first trimester should be avoided entirely regardless of clinical severity
D) Intravenous amphotericin B deoxycholate is the only antifungal considered safe in the first trimester because it does not cross the placenta and is the preferred agent for all fungal infections including oropharyngeal candidiasis during pregnancy, with oral antifungals contraindicated due to placental transfer concerns
E) Topical clotrimazole troches are the preferred treatment because clotrimazole has a Category A pregnancy safety rating from clinical trials in the first trimester demonstrating no teratogenic risk, whereas nystatin's pregnancy safety has never been evaluated in controlled trials and should be considered experimental in this population

ANSWER: B

Rationale:

Nystatin oral suspension (100,000 units/mL) at 400,000 to 600,000 units four times daily, swished around the mouth and swallowed or expectorated, is the appropriate first-line treatment for oropharyngeal candidiasis during pregnancy. The pharmacological basis for its safety in pregnancy is straightforward: nystatin is essentially not absorbed from the gastrointestinal tract. Because the drug remains confined to the gastrointestinal lumen after swallowing, systemic maternal drug exposure is negligible and fetal drug exposure does not occur. This non-absorbed profile makes nystatin the preferred option for mucosal candidiasis in pregnancy, where systemic azoles are generally avoided — particularly oral fluconazole, which has been associated with dose-dependent teratogenicity (specifically cardiac septal defects and skeletal abnormalities) in studies of first-trimester exposure at higher doses.

Option A: Option A is incorrect; fluconazole's safety in the first trimester is not well established for repeated or moderate doses — multiple pharmacoepidemiological studies have raised concerns about associations between first-trimester fluconazole exposure and adverse fetal outcomes, and it is generally avoided in the first trimester.
Option C: Option C is incorrect; oropharyngeal candidiasis does not reliably self-limit in inhaled corticosteroid-treated patients, and withholding all antifungal treatment during the first trimester regardless of severity is not appropriate clinical management — safe topical options exist.
Option D: Option D is incorrect; intravenous amphotericin B deoxycholate is not indicated for oropharyngeal candidiasis and is not the standard antifungal for mucosal infections during pregnancy; it is reserved for serious systemic or invasive fungal infections.
Option E: Option E is incorrect; while topical clotrimazole troches are a reasonable option for oropharyngeal candidiasis in pregnancy, the claim that nystatin's pregnancy safety has never been evaluated and should be considered experimental misrepresents its long-established clinical use — nystatin is one of the most well-established topical antifungals used in pregnancy with decades of safety data.

11. A 48-year-old woman with acute myeloid leukemia has been receiving fluconazole prophylaxis for 16 weeks during consolidation chemotherapy. She develops breakthrough Candida glabrata fungemia. Antifungal susceptibility testing shows fluconazole resistance and elevated amphotericin B minimum inhibitory concentrations above the susceptibility breakpoint. The infectious disease team asks why a patient on azole prophylaxis has developed reduced susceptibility to amphotericin B, a drug to which she has never been exposed. Which of the following best explains this finding and guides the choice of appropriate therapy?

A) The elevated amphotericin B MICs reflect laboratory variability rather than true clinical resistance; amphotericin B therapy should be initiated at standard doses because in vitro MIC results for polyene antifungals do not predict clinical outcomes and should not be used to guide therapy decisions
B) The elevated amphotericin B MICs reflect CDR1 and MDR1 efflux pump upregulation selected by prolonged fluconazole exposure; because these pumps non-selectively export all antifungal classes including polyenes, both azoles and amphotericin B are now ineffective, and echinocandins should be used since they are not substrates for CDR1 or MDR1
C) Prolonged fluconazole exposure selected for mutations in ERG3 or ERG11 — genes encoding enzymes in the ergosterol biosynthesis pathway that is the shared target of both azoles and amphotericin B; the resulting reduction in membrane ergosterol eliminates the binding target for amphotericin B, explaining co-selected cross-resistance without prior polyene exposure; an echinocandin is the appropriate therapy pending full susceptibility results
D) The elevated amphotericin B MICs reflect Candida glabrata biofilm formation on the central venous catheter, which produces a physical barrier reducing drug penetration to the organism rather than a genetic resistance mechanism; catheter removal will restore amphotericin B susceptibility without the need for alternative antifungal therapy
E) The elevated amphotericin B MICs reflect competitive inhibition of ergosterol-binding sites by residual fluconazole molecules that remain bound to the Candida glabrata cell membrane after prolonged prophylaxis; once fluconazole is discontinued and washes out over 48 to 72 hours, the ergosterol target becomes available again and amphotericin B susceptibility is restored

ANSWER: C

Rationale:

This case illustrates the mechanistic link between azole and polyene resistance arising from a shared biosynthetic target. Both azoles and amphotericin B ultimately depend on ergosterol: azoles inhibit its synthesis (through lanosterol 14-alpha-demethylase, ERG11), and amphotericin B binds to it in the assembled fungal cell membrane. Under prolonged selective pressure from fluconazole, Candida glabrata can accumulate mutations in ERG3 (C-5 sterol desaturase) or ERG11 that reduce membrane ergosterol content or alter sterol composition. ERG3 mutations cause accumulation of 14-alpha-methylfecosterol, an abnormal sterol that cannot serve as the AmB binding target. ERG11 mutations reduce ergosterol production efficiency, lowering membrane ergosterol below the threshold needed for AmB pore assembly. Both mechanisms reduce the pharmacological target available for AmB — explaining cross-resistance to a drug the patient has never received. An echinocandin (caspofungin, micafungin, or anidulafungin) targets beta-1,3-glucan synthase, a mechanism entirely independent of the ergosterol pathway, and is the appropriate empirical therapy while full susceptibility testing is completed.

Option A: Option A is incorrect; amphotericin B MICs above the susceptibility breakpoint in Candida glabrata are clinically meaningful and should not be dismissed as laboratory variability — the ERG gene mutation mechanism for polyene resistance is well established.
Option B: Option B is incorrect; CDR1 and MDR1 efflux pumps are the primary mechanisms of azole resistance in Candida but do not export amphotericin B — polyene resistance in this setting is mediated by membrane target reduction, not efflux.
Option D: Option D is incorrect; while biofilm can reduce antifungal efficacy generally, it does not selectively elevate amphotericin B MICs on in vitro susceptibility testing, and catheter removal alone does not restore pharmacological susceptibility.
Option E: Option E is incorrect; residual fluconazole molecules competing for ergosterol binding sites is a pharmacologically fabricated mechanism — fluconazole binds CYP51 intracellularly and does not occupy ergosterol binding sites on the cell membrane surface; the reduced AmB susceptibility reflects genetic changes in the organism, not reversible drug-drug competition.